Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
Are able and willing to provide written informed consent, attend all scheduled visits, and comply with all trial procedures and follow-up
Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
You may not be if
Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome
Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk
